News

Filter

Current filters:

EisaiOncology

1 to 9 of 80 results

Eisai's Halaven to stay on UK Cancer Drugs Fund list pending reconsideration

Eisai's Halaven to stay on UK Cancer Drugs Fund list pending reconsideration

11-03-2015

Japanese drug major Eisai has announced that its drug Halaven (eribulin) will remain on the UK's National…

EisaiHalavenOncologyPharmaceuticalRegulationUK

Eisai and Merck enter cancer research collaboration

05-03-2015

Japanese drug major Eisai saw its shares gain 7.15% to 6,732 yen after it announced it had entered into…

EisaiHalavenKeytrudaLenvimaMerck & CoOncologyPharmaceuticalResearch

First launch for Eisai’s Lenvima, in the USA

First launch for Eisai’s Lenvima, in the USA

03-03-2015

The US subsidiary of Japanese pharma major Eisai has now launched its in-house developed novel anticancer…

EisailenvatinibLenvimaMarkets & MarketingOncologyPharmaceuticalRare diseases

UPDATE: FDA approves Eisai’s Lenvima for a type of thyroid cancer and expands use of Banzel

UPDATE: FDA approves Eisai’s Lenvima for a type of thyroid cancer and expands use of Banzel

14-02-2015

The US Food and Drug Administration on Friday granted approval for Japanese pharma major Eisai’s Lenvima…

BanzelEisailenvatinibLenvimaNeurologicalOncologyPharmaceuticalRare diseasesRegulationUSA

Helsinn grants Stendhal rights to NEPA in several Latin America countries

02-02-2015

Family-run Swiss oncology specialist Helsinn has granted exclusive rights to Mexico-based Especificos…

AkynzeoEisaiHelsinnLicensingNEPAnetupitantOncologypalonosetronPharmaceuticalSouth AmericaStendhal

German Federal Joint Committee confirms 'considerable' benefit of Eisai's Halaven in breast cancer

German Federal Joint Committee confirms 'considerable' benefit of Eisai's Halaven in breast cancer

23-01-2015

The German Federal Joint Committee has confirmed the ‘considerable’ additional benefit of Japanese…

EisaiGermanyHalavenOncologyPharmaceuticalRegulation

Helsinn settles with Sandoz over Aloxi in USA

12-01-2015

Privately-held Swiss cancer specialist Helsinn Group say it has entered into a settlement agreement with…

AloxiEisaiGenericsHelsinn GroupLegalNovartisOncologyPatentsSandozUSA

Drugmakers “outraged” at England's Cancer Drugs Fund decision to remove drugs from coverage

Drugmakers “outraged” at England's Cancer Drugs Fund decision to remove drugs from coverage

08-01-2015

England’s Cancer Drugs Fund is overspent and 42 drugs are being reassessed as price caps are brought…

AvastinEisaiHalavenHealthcareJevtanaKadcylaOncologyPharmaceuticalPricingRocheSanofiUKZaltrap

1 to 9 of 80 results

Back to top